Glaser Pediatric Research Network   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Palo Alto CA United States (2000)

Organization Overview

First Clinical Trial
2002
NCT00209469
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

alendronic acid (fosamax) (2 trials)

sitagliptin (januvia) (2 trials)

Drugs in Phase 2 Trials (2)

doxorubicin (Doxil) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Diseases, Metabolic (Phase 3)

Obesity (Phase 3)

Osteoporosis (Phase 3)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4